Abstract
-
The controversy surrounding the off-label use of hydroxychloroquine (HCQ) for COVID-19 highlights the inherent inequality of disease conditions. In this brief ethics explainer, we argue that we need to make explicit the clinical and non-clinical factors that determine the inequality of diseases. The varying appraisals of disease inequality, in turn, reveal the values that govern the contrasting prioritisation among health care institutions.